Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004259 | 0.86 | KMT2A (0.63) | KMT2ASMN1; SMN2MAPK1MEN1ALDH1A1 | |
| SCHEMBL4004624 | 0.86 | MAPK1 (0.56) | KMT2ASMN1; SMN2MAPK1MEN1TAAR1 | |
| SCHEMBL4006274 | 0.83 | KMT2A (0.59) | KMT2ASMN1; SMN2MEN1ALDH1A1TRPV1 | |
| SCHEMBL4003247 | 0.83 | LMNA (0.53) | KMT2ASMN1; SMN2ALDH1A1TRPV1TP53 | |
| SCHEMBL4002538 | 0.82 | KMT2A (0.55) | KMT2ASMN1; SMN2ALDH1A1TRPV1TP53 | |
| SCHEMBL3999435 | 0.82 | MAPK1 (0.60) | KMT2ASMN1; SMN2MAPK1MEN1TAAR1 | |
| SCHEMBL4004550 | 0.82 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2ALDH1A1TRPV1KDM4E | |
| SCHEMBL4004685 | 0.82 | KMT2A (0.50) | KMT2ASMN1; SMN2MEN1TRPV1HPGD | |
| SCHEMBL4006848 | 0.80 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1TRPV1 | |
| SCHEMBL4005288 | 0.79 | MAPK1 (0.70) | KMT2AMAPK1MEN1TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885SMN1; SMN2 1213/4885MAPK1 2344/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885SMN1; SMN2 1213/4885MAPK1 2344/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | KMT2A 1792/4885SMN1; SMN2 1699/4885MAPK1 3775/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885SMN1; SMN2 1213/4885MAPK1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.